
We claim:

1. Use of a composition comprising an antibody drug conjugate in the manufacture of a medicament for the treatment of cancer, wherein the cancer expresses CCR7, in a human subject in need thereof, wherein the antibody drug conjugate comprises the following formula:



Ab-MPET-DM4

wherein n is 3 to 4, and Ab is an antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:47, and a light chain comprising the amino acid sequence of SEQ ID NO:63; or a pharmaceutically acceptable salt thereof,

and wherein the antibody drug conjugate is to be administered to said human subject at 0.1 mg/kg to 10 mg/kg.

2. The use according to claim 1, wherein the antibody drug conjugate is in a non-salt form.

3. The use according to claim 1 or claim 2, wherein the cancer is selected from the group consisting of chronic lymphocytic leukemia (CLL), peripheral T cell lymphomas (PTCL) such as adult T-cell leukemia/lymphoma (ATLL) and anaplastic large-cell lymphoma (ALCL), Non-Hodgkin’s lymphoma (NHL) such as mantle cell lymphoma (MCL), Burkitt’s lymphoma, diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL), and non-small cell lung cancer.

4. The use according to any one of the preceding claims, wherein the cancer is a relapsed or refractory cancer.

5. The use according to any one of the preceding claims, wherein the antibody drug conjugate is to be administered to the human subject once every 2 weeks or once every 3 weeks.

6. The use according to claim 5, wherein the antibody drug conjugate is to be administered to the human subject once every 3 weeks.

7. The use according to any one of the preceding claims, wherein the subject is to be treated for 1 cycle, 2 cycles, 3 cycles, 4 cycles, or 5 cycles.

8. The use according to any one of the preceding claims, wherein the antibody drug conjugate is to be administered to the human subject intravenously.

9. The use according to any one of the preceding claims, wherein the antibody drug conjugate is to be administered to said human subject at a dose of 2.4 mg/kg or 3.6 mg/kg.

10. The composition for use according claim 9, wherein the antibody drug conjugate is to be administered to said human subject at a dose of about 3.6 mg/kg.